# A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

> **NCT05736107** · PHASE2 · COMPLETED · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 107 (actual)

## Conditions studied

- Subcutaneous Fat

## Interventions

- **DRUG:** CBL-514 Injection
- **OTHER:** 0.9% Sodium Chloride

## Key facts

- **NCT ID:** NCT05736107
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-30
- **Primary completion:** 2024-05-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736107, "A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05736107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*